Charles CPA - Oragenics Executive Chairman
| OGEN Stock | USD 0.32 0.03 10.34% |
Chairman
Charles CPA is Executive Chairman of Oragenics
| Age | 72 |
| Address | 4902 Eisenhower Boulevard, Tampa, FL, United States, 33634 |
| Phone | 813 286 7900 |
| Web | https://www.oragenics.com |
Oragenics Management Efficiency
The company has return on total asset (ROA) of (2.1989) % which means that it has lost $2.1989 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.5472) %, meaning that it created substantial loss on money invested by shareholders. Oragenics' management efficiency ratios could be used to measure how well Oragenics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 30th of November 2024, Return On Tangible Assets is likely to grow to -3.95. In addition to that, Return On Capital Employed is likely to grow to -6.27. At this time, Oragenics' Total Assets are very stable compared to the past year. As of the 30th of November 2024, Non Current Assets Total is likely to grow to about 1.2 M, while Total Current Assets are likely to drop about 3.7 M.Management Performance
| Return On Equity | -4.55 | ||||
| Return On Asset | -2.2 |
Oragenics Leadership Team
Elected by the shareholders, the Oragenics' board of directors comprises two types of representatives: Oragenics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oragenics. The board's role is to monitor Oragenics' management team and ensure that shareholders' interests are well served. Oragenics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oragenics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Martin MSc, VP Research | ||
| MD MA, Chief Advisor | ||
| IV FACEP, Chief Officer | ||
| Kimberly Murphy, CEO Director | ||
| Erik Emerson, Chief Officer | ||
| Janet Huffman, Secretary CFO | ||
| Michael CPA, S CFO | ||
| Charles CPA, Executive Chairman | ||
| Joseph Redmond, President Officer | ||
| Frederick Telling, Independent Chairman of the Board | ||
| Greg Gironda, Chief Officer |
Oragenics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Oragenics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.55 | ||||
| Return On Asset | -2.2 | ||||
| Current Valuation | 2.53 M | ||||
| Shares Outstanding | 12.21 M | ||||
| Shares Owned By Insiders | 25.40 % | ||||
| Shares Owned By Institutions | 11.13 % | ||||
| Number Of Shares Shorted | 191.09 K | ||||
| Price To Earning | (2.28) X | ||||
| Price To Book | 2.40 X | ||||
| Price To Sales | 520.18 X |
Pair Trading with Oragenics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oragenics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oragenics will appreciate offsetting losses from the drop in the long position's value.Moving together with Oragenics Stock
Moving against Oragenics Stock
| 0.71 | BHC | Bausch Health Companies | PairCorr |
| 0.68 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.64 | GILD | Gilead Sciences | PairCorr |
| 0.6 | GANX | Gain Therapeutics | PairCorr |
| 0.54 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
The ability to find closely correlated positions to Oragenics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oragenics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oragenics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oragenics to buy it.
The correlation of Oragenics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oragenics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oragenics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Oragenics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oragenics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Oragenics Stock, please use our How to Invest in Oragenics guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oragenics. If investors know Oragenics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oragenics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.97) | Revenue Per Share 0.002 | Quarterly Revenue Growth (0.91) | Return On Assets (2.20) | Return On Equity (4.55) |
The market value of Oragenics is measured differently than its book value, which is the value of Oragenics that is recorded on the company's balance sheet. Investors also form their own opinion of Oragenics' value that differs from its market value or its book value, called intrinsic value, which is Oragenics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oragenics' market value can be influenced by many factors that don't directly affect Oragenics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oragenics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oragenics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oragenics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.